Announces Business Update Conference Call on Monday, August 5, 2013 at 1:15 pm PT
CUPERTINO, Calif. – August 1, 2013 – Aemetis, Inc. (OTC: AMTX), an advanced renewable fuels and biochemicals company, today filed its 10Q with the SEC for the quarter ending June 30, 2013 and announced that the company will host a business update conference call:
Date: Monday, August 5, 2013
Time: 1:15 pm Pacific Time
Conference Number: +1 (559) 726-1300
Access code: 166576
Attendees may submit questions to management prior to Noon Pacific Time on August 2, 2013 using the following email address: firstname.lastname@example.org.
Highlights from the 10-Q filing include: gross margin for the quarter ended June 30, 2013 increased to $3.7 million on worldwide revenues of $47 million; sales in India for the first half of 2013 increased to $23 million, and Third Eye Capital, our senior lender, provided a one-year extension on the senior debt financing. The 10Q filing is available on the Aemetis website in the Investor section.
After August 5th, the webcast will be archived on the Company’s website (www.aemetis.com) under Investors/Conference Calls. The voice recording will also be available for 90 days by dialing +1 (559) 726-1399, access code 166576.
Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of first generation ethanol and biodiesel plants into advanced biorefineries. Aemetis owns and operates a 60 million gallon ethanol renewable fuels plant in California; and built, owns and operates a 50 million gallon capacity biodiesel advanced fuels and renewable chemicals production facility on the east coast of India. Aemetis operates a research and development laboratory at the Maryland Biotech Center, and holds five granted patents on its Z-microbe and related technology for the production of renewable fuels and chemicals. For additional information about Aemetis, please visit www.aemetis.com.